San Leng (Sparganium stoloniferum) Pharmacology — The Blood-Breaking Bur-Reed Rhizome Behind Dit Da Plasters, Zheng-Jia Liniments, and Modern Anti-Angiogenic Research

If you have read our companion piece on E Zhu (Curcuma phaeocaulis), you already know half of one of Chinese medicine’s most surgically precise herbal couples. San Leng (三棱), the rhizome of Sparganium stoloniferum Buch.-Ham., is the other half — and the two are so deeply welded together in classical pharmacy that most dit da masters, oncology-adjacent TCM doctors, and gynecology specialists simply order them as one line item: “三棱莪术 (San Leng E Zhu), equal parts, vinegar-fried.”

But the two are not interchangeable. The classical aphorism states it cleanly: 三棱破血中之气，莪术破气中之血 — “San Leng breaks the qi within the blood; E Zhu breaks the blood within the qi.” San Leng is the harder, more cutting partner. It is the chisel that splits abdominal masses, the topical agent that softens fibrotic dit-da nodules, and — in modern pharmacology — the source of sparstolonin B, one of the most-studied small-molecule anti-angiogenic agents to come out of TCM in the last fifteen years.

This article maps San Leng’s chemistry, mechanism, classical roles, processing pharmacology, modern oncology and gynecology research, and the narrow safety window that has kept it from being a casual ingredient.

1. Botany and Pharmacognosy

Sparganium stoloniferum is an aquatic perennial in the Typhaceae family (formerly Sparganiaceae) — a relative of the cattail, growing in shallow ponds, slow-moving streams, and paddy edges across China, Korea, Japan, and Mongolia. The medicinal organ is the dried tuberous rhizome, harvested in autumn or winter after the aerial parts wither.

Properly processed San Leng is conical, slightly compressed, 2–6 cm long, with a pale yellow to grayish-white cut surface and visible vascular bundles arranged in a ring. The Chinese name 三棱 — literally “three-edged” — refers to the triangular cross-section of the aerial stem, though commercial slices are usually round or oval. A rasp-like surface texture, pungent-bitter taste, and dense, slightly oily cut surface distinguish authentic San Leng from common adulterants such as Scirpus yagara (“Hei San Leng,” the rhizome of a Cyperaceae plant once widely substituted in northern China) and Carex species.

This botanical confusion matters pharmacologically. Scirpus yagara contains a different chemical profile (more stilbenes, fewer phenylpropanoid glycerides) and a milder pharmacology — so historical formulas calibrated on true Sparganium San Leng can be unpredictably weaker if the wrong species is substituted. Modern Chinese Pharmacopoeia editions explicitly require Sparganium stoloniferum and reject Scirpus yagara as a separate, non-equivalent material.

2. Chemistry — Why Sparstolonin B Changed the Conversation

San Leng’s pharmacology used to be described in vague terms: “improves microcirculation, anti-thrombotic, anti-tumor.” Modern isolation work, particularly the Journal of Natural Products paper by Shirota et al. (1996) and the subsequent two decades of phytochemical work, identified a much more specific chemical signature:

2.1 Phenylpropanoid Glycerides and Glycosides

The most characteristic compound class. 1-O-feruloyl-, 1-O-p-coumaroyl-, and 1-O-caffeoyl-glycerols — small molecules combining cinnamic-acid-type acyl groups with glycerol — give San Leng its anti-platelet aggregation and mild anti-inflammatory profile. These are absent from Scirpus yagara and serve as marker compounds for authentication.

2.2 Sparstolonins (especially Sparstolonin B)

A class of isocoumarin compounds, with sparstolonin B (SsnB) as the standout. SsnB has emerged as a selective TLR2 and TLR4 antagonist with dose-dependent inhibition of endothelial tube formation, VEGF-driven angiogenesis, and pro-inflammatory cytokine release. The 2013 PLOS One paper by Bateman et al. demonstrated that SsnB blocks endothelial cell cycle progression in the G0/G1 phase — providing a clean molecular explanation for the classical “softens masses, dispels stasis” indication.

2.3 Sesquiterpenes Shared with Curcuma

San Leng contains β-elemene, dehydrocostuslactone, and germacrone — the same family of sesquiterpene compounds that drive E Zhu’s blood-moving pharmacology. This molecular overlap is precisely why the herbal pair works synergistically: each rhizome contributes overlapping sesquiterpenes plus its own unique compounds (sparstolonins from San Leng, curcumol/curdione from E Zhu).

2.4 Other Constituents

Flavonoids (sparganin-type), steroidal saponins, polysaccharides (with reported immunomodulatory activity), benzeneethanol, hexadecanoic acid, azelaic acid, 1,4-benzenediol, and trace alkaloids including a peculiar N-heterocyclic Al complex glycoside isolated by Hu et al., the pharmacological significance of which is still being studied.

3. Mechanism of Action — Three Pharmacological Pillars

3.1 Anti-Platelet / Anti-Thrombotic

The phenylpropanoid glycerides and certain flavonoid components inhibit ADP- and collagen-induced platelet aggregation in vitro, and modestly reduce plasma fibrinogen and whole-blood viscosity in animal models. This pharmacology supplies the molecular substrate for the classical descriptor “breaks blood, dispels stasis” — and explains why San Leng is contraindicated alongside warfarin, DOACs, antiplatelets, and the immediate pre/post-operative window.

3.2 Anti-Angiogenic / Anti-Tumor

Sparstolonin B suppresses endothelial proliferation, VEGF-induced tube formation, and migration through TLR2/4 antagonism and downstream NF-κB suppression. Beyond SsnB, dehydrocostuslactone and β-elemene contribute apoptotic mechanisms in tumor cell lines (gastric, lung, prostate, ovarian). The PMC 2017 paper on “Antigastric Cancer Activity of San Leng Powder Extract” documented apoptosis in SGC-7901 xenografts in Balb/C mice; network-pharmacology work on the San Leng–E Zhu pair has mapped synergistic effects against lung cancer and castration-resistant prostate cancer.

This is the pharmacological reason San Leng appears as an oncology-adjunct herb in modern integrative TCM oncology departments — not as a primary chemotherapy but as a stasis-dispersing co-treatment.

3.3 Anti-Estrogenic / Anti-Fibrotic

A pharmacological feature shared with E Zhu but more prominent in San Leng: extracts antagonize ER-α signaling and suppress VEGF/FGF-1 in animal models. This is the molecular substrate for the herb’s classical use in endometriosis, uterine fibroids (zi gong ji liu), and “zheng-jia” (concretions and conglomerations), and also the reason it has reproductive-toxicity concerns in pregnancy.

4. Classical Roles and Formula Anchoring

4.1 The San Leng–E Zhu Couple

The single most-referenced application. The pair appears as the workhorse blood-breaker in dozens of classical formulas:

4.2 Dit Da Plasters and Liniments

In die da (跌打) trauma medicine, San Leng appears where chronic, hardened, fibrotic masses must be softened — old hematomas that have organized into nodules, tendon adhesions, and palpable scar-like induration after deep tissue injury. It does not appear in early-phase acute trauma formulas (those favor Hong Hua, Tao Ren, and Ru Xiang). San Leng is for week three onward, when stasis has crystallized into fibrosis.

4.3 Tincture and Plaster Roles

In dit-da plasters (gao yao), San Leng is generally vinegar-fried, powdered, and incorporated into the plaster base with E Zhu and frequently with Su Mu and Tu Bie Chong. The vinegar processing serves two roles: it directs the herb’s action to the Liver channel (where blood stasis is held in TCM theory) and softens the herb’s harshness so the topical application is less locally irritating.

5. Processing Pharmacology — Why Vinegar Frying Matters

San Leng is almost never used raw in oral or topical preparations. The dominant processing method is cu zhi (醋炙) — vinegar frying — which involves:

  1. Soaking sliced rhizome in rice vinegar (typically 20% w/w).
  2. Stir-frying until the slices are dry, darkened, and aromatic.

Pharmacologically, vinegar processing changes the chemistry meaningfully:

This is one of the few cases where the TCM processing tradition and modern pharmacology agree on both the what and the why — vinegar frying genuinely changes the pharmacological profile in the direction described by classical sources.

6. Medicated Oils, Liniments, and Topical Use

San Leng appears in the topical pharmacy in several roles:

6.1 Dit Da Jow Tinctures

In hard-style martial arts liniments — those formulated for chronic training injuries rather than acute bruising — San Leng appears alongside E Zhu, Su Mu, Mo Yao (myrrh), Hong Hua, and Dragon’s Blood. The 6–12 month alcohol maceration typical of dit da jow extracts both the phenylpropanoid glycerides and the lipophilic sesquiterpenes.

6.2 Mass-Softening Plasters

The “zheng-jia gao” tradition — topical plasters applied to palpable abdominal or pelvic masses — uses San Leng and E Zhu as anchors, often layered over Mugwort (Ai Ye) moxa or applied warm. This tradition continues in modern TCM gynecology departments for uterine fibroid and endometriosis adjunct care, though plaster delivery is a slow modality and not a substitute for primary medical management.

6.3 Soft-Tissue Adhesion Liniments

For post-injury scar tissue and tendon adhesions, San Leng-containing liniments are applied with deep friction massage — the combination of mechanical disruption and the herb’s anti-fibrotic/anti-proliferative pharmacology is the working hypothesis, though direct clinical evidence is limited.

San Leng is not appropriate for inflammatory acute injuries (first 72 hours), for any open or weeping wound, or over the abdomen during pregnancy.

7. Modern Pharmacology Research and Clinical Use

7.1 Oncology Adjunct

San Leng–E Zhu network pharmacology studies (PMC 2021 lung cancer paper, PMC 2024 castration-resistant prostate cancer paper) have mapped multi-target effects spanning VEGF/VEGFR signaling, PI3K-Akt, MAPK, and apoptosis-related pathways. The current research positions San Leng not as a standalone anti-tumor agent but as a sensitizer that supports the action of conventional chemotherapy, reduces VEGF-driven angiogenesis, and may improve hemorheological parameters in cancer patients.

7.2 Endometriosis and Fibroids

Modern gynecology research supports the classical indication: San Leng-containing formulations reduce lesion volume in animal endometriosis models, antagonize ER-α, and suppress angiogenesis at the implant site. Clinical use in China is typically as an adjunct to hormonal therapy, not a replacement.

7.3 Hepatic Fibrosis and Cirrhosis

A growing research line: San Leng’s anti-fibrotic pharmacology is being explored in liver-fibrosis models, with the rationale that “blood-breaking, mass-softening” maps onto the modern target of hepatic stellate cell activation. Evidence is still preclinical.

7.4 Anti-Inflammatory and Pain Pharmacology

The phenylpropanoid glycerides and sesquiterpenes provide a mild anti-inflammatory and analgesic effect, particularly when San Leng is paired with Yan Hu Suo in qi-and-blood-stasis pain formulas.

8. Safety, Contraindications, and Pregnancy

San Leng has a narrower safety window than many medicated-oil ingredients, and this defines who can use it and how.

8.1 Absolute Contraindications

8.2 Topical Considerations

For dit-da and mass-softening plasters/liniments containing San Leng:

8.3 Drug Interactions

8.4 Quality and Sourcing

Two pharmacopeial issues to know:

  1. Species substitution — Scirpus yagara (“Hei San Leng”) still appears in some markets, particularly cheaper bulk supplies. Insist on Sparganium stoloniferum explicitly.
  2. Processing state — most clinical formulas call for vinegar-fried (cu San Leng); raw San Leng has a harsher pharmacology and is rarely appropriate.

9. Putting San Leng in Context

If E Zhu is the qi-breaking half of the pair, San Leng is the blood-breaking half — but in the herbal pharmacy, “blood-breaking” specifically means dissolving organized, palpable, fibrotic mass-like stasis. This is the most aggressive tier of stasis-dispersing therapy in classical Chinese medicine, and San Leng is the chisel.

For a brand-strategy or formulator’s perspective, San Leng signals: this is a chronic stasis product, not an acute bruise oil. Liniments anchored on San Leng + E Zhu are positioning themselves for the post-acute window — old injuries, organized hematomas, fibrotic nodules, and mass-softening indications. They should not be marketed for first-aid use, sprain-and-strain, or pregnancy-safe applications.

For practitioners, San Leng’s clinical profile pairs with Yan Hu Suo for pain, Tao Ren and Hong Hua for general blood-moving, and [Mu Xiang]-type qi movers for severe stagnation-with-mass presentations. In an oncology-adjacent setting it pairs with Ban Mao (cantharidin) and modern conventional therapy under specialist supervision — a combination that should never be self-administered.

10. Summary

San Leng (Sparganium stoloniferum) is the bur-reed rhizome that, with E Zhu, anchors the most aggressive blood-stasis-breaking class in Chinese pharmacy. Its pharmacological signature — phenylpropanoid glycerides for anti-platelet activity, sparstolonin B for anti-angiogenesis, and shared sesquiterpenes with E Zhu — provides a coherent molecular basis for indications that have not changed in eight centuries: abdominal masses, endometriosis, fibroids, and organized chronic stasis injuries.

It is a topical and oral herb with real teeth: real reproductive toxicity, real bleeding risk, and real interactions with modern anticoagulants and hormonal therapies. Used appropriately — vinegar-processed, in classical pairs, with attention to the safety profile — it remains one of the most surgically precise herbs in the dit-da, gynecology, and integrative-oncology repertoire.

References and Further Reading

Related reading on the San Leng cluster: E Zhu Pharmacology (the qi-breaking twin), Yan Hu Suo Pharmacology (pain partner), Tao Ren Pharmacology and Hong Hua Pharmacology (general blood movers), and Ban Mao Pharmacology (oncology-adjacent partner under supervision).